A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
Price : $35 *
At a glance
- Drugs Briciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Nov 2019.
- 31 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Aug 2019.